Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Retrospective analysis of survival in patients with leptomeningeal carcinomatosis from lung adenocarcinoma treated with erlotinib and gefitinib.

Kashima J, Okuma Y, Miwa M, Hosomi Y.

Jpn J Clin Oncol. 2017 Apr 1;47(4):357-362. doi: 10.1093/jjco/hyw206.

PMID:
28064206
2.

Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer.

Lee E, Keam B, Kim DW, Kim TM, Lee SH, Chung DH, Heo DS.

J Thorac Oncol. 2013 Aug;8(8):1069-74. doi: 10.1097/JTO.0b013e318294c8e8.

3.

Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.

Cho KM, Keam B, Kim TM, Lee SH, Kim DW, Heo DS.

Korean J Intern Med. 2015 Nov;30(6):891-8. doi: 10.3904/kjim.2015.30.6.891. Epub 2015 Oct 30.

4.

Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib faliure.

Yang H, Yang X, Zhang Y, Liu X, Deng Q, Zhao M, Xu X, He J.

Target Oncol. 2015 Mar;10(1):135-40. doi: 10.1007/s11523-014-0326-9. Epub 2014 Jul 2.

PMID:
24985049
5.
6.

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.

Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.

Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.

PMID:
22457323
7.

Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis.

Uruga H, Moriguchi S, Takahashi Y, Ogawa K, Murase K, Mochizuki S, Hanada S, Takaya H, Miyamoto A, Morokawa N, Kishi K.

BMC Cancer. 2018 Aug 16;18(1):825. doi: 10.1186/s12885-018-4743-5.

8.

Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.

Sohn HS, Kwon JW, Shin S, Kim HS, Kim H.

J Clin Pharm Ther. 2015 Dec;40(6):661-71. doi: 10.1111/jcpt.12332. Epub 2015 Nov 17.

PMID:
26573867
9.

Promising Effects of Afatinib on Leptomeningeal Carcinomatosis Derived from Erlotinib-resistant Lung Adenocarcinoma.

Sekine A, Kato T, Iwasawa T, Baba T, Suido A, Sakuranaka H, Futaki M, Ogura T.

Intern Med. 2016;55(17):2457-61. doi: 10.2169/internalmedicine.55.6102. Epub 2016 Sep 1.

10.

Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy.

Masuda T, Hattori N, Hamada A, Iwamoto H, Ohshimo S, Kanehara M, Ishikawa N, Fujitaka K, Haruta Y, Murai H, Kohno N.

Cancer Chemother Pharmacol. 2011 Jun;67(6):1465-9. doi: 10.1007/s00280-011-1555-6. Epub 2011 Jan 28.

PMID:
21274533
11.

Cerebrospinal Fluid Penetration Rate and Efficacy of Afatinib in Patients with EGFR Mutation-positive Non-small Cell Lung Cancer with Leptomeningeal Carcinomatosis: A Multicenter Prospective Study.

Tamiya A, Tamiya M, Nishihara T, Shiroyama T, Nakao K, Tsuji T, Takeuchi N, Isa SI, Omachi N, Okamoto N, Suzuki H, Okishio K, Iwazaki A, Imai K, Hirashima T, Atagi S.

Anticancer Res. 2017 Aug;37(8):4177-4182.

PMID:
28739703
12.

MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR-mutant Lung Cancer.

Nanjo S, Arai S, Wang W, Takeuchi S, Yamada T, Hata A, Katakami N, Okada Y, Yano S.

Mol Cancer Ther. 2017 Mar;16(3):506-515. doi: 10.1158/1535-7163.MCT-16-0522. Epub 2017 Jan 30.

14.

Clinical Impact of Gastric Acid-Suppressing Medication Use on the Efficacy of Erlotinib andĀ Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFRĀ Mutations.

Zenke Y, Yoh K, Matsumoto S, Umemura S, Niho S, Ohmatsu H, Goto K, Ohe Y.

Clin Lung Cancer. 2016 Sep;17(5):412-418. doi: 10.1016/j.cllc.2016.01.006. Epub 2016 Feb 5.

PMID:
26944770
15.

Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure.

Sasaki S, Yoshioka Y, Ko R, Katsura Y, Namba Y, Shukuya T, Kido K, Iwakami S, Tominaga S, Takahashi K.

Respir Investig. 2016 Jan;54(1):14-9. doi: 10.1016/j.resinv.2015.07.001. Epub 2015 Aug 30.

PMID:
26718140
16.

Successful EGFR-TKI rechallenge of leptomeningeal carcinomatosis after gefitinib-induced interstitial lung disease.

Nakamichi S, Kubota K, Horinouchi H, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Tamura T.

Jpn J Clin Oncol. 2013 Apr;43(4):422-5. doi: 10.1093/jjco/hyt012. Epub 2013 Feb 13.

PMID:
23410901
17.

Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.

Greenhalgh J, Bagust A, Boland A, Dwan K, Beale S, Hockenhull J, Proudlove C, Dundar Y, Richardson M, Dickson R, Mullard A, Marshall E.

Health Technol Assess. 2015 Jun;19(47):1-134. doi: 10.3310/hta19470. Review.

18.

Icotinib might be effective for the treatment of leptomeningeal carcinomatosis in non-small cell lung cancer with sensitive EGFR mutations.

Gong L, Xiong M, Huang Z, Miao L, Fan Y.

Lung Cancer. 2015 Sep;89(3):268-73. doi: 10.1016/j.lungcan.2015.06.001. Epub 2015 Jun 24.

PMID:
26141219
19.

An unexpected response to second line EGFR inhibitor in relapsing leptomeningeal carcinomatosis from lung adenocarcinoma raises questions on differential mechanisms of action of these agents.

Ghosn M, Assi T, El Rassy E, Moussa T, Kattan J.

Bull Cancer. 2017 Apr;104(4):385-387. doi: 10.1016/j.bulcan.2016.12.006. Epub 2017 Jan 26. No abstract available.

PMID:
28131317
20.

[Efficacy of erlotinib after the failure of gefitinib in patients with metastasis of non-small cell lung cancer with unknown EGFR mutation status].

Wang Y, Li JL, Wang ZP, Hao XZ, Wang B, Zhang XR, Shi YK.

Zhonghua Zhong Liu Za Zhi. 2012 Oct;34(10):780-4. doi: 10.3760/cma.j.issn.0253-3766.2012.10.013. Chinese.

PMID:
23291074

Supplemental Content

Support Center